Longevity & AgingLight Therapy Boosts Vision and Slows AMD Progression Over 2 Years
The LIGHTSITE III randomized controlled trial evaluated multiwavelength photobiomodulation (PBM) using the Valeda device (590, 660, and 850 nm) in 148 eyes of 100 patients with dry age-related macular degeneration over 24 months. PBM was delivered in nine-session series every four months. At the 21-month primary endpoint, PBM-treated eyes gained an average of 6.2 ETDRS letters compared to sham, a statistically significant difference (P=0.0036). Notably, disease progression to geographic atrophy was dramatically reduced: only 6.8% of PBM-treated eyes progressed versus 24.0% in the sham group (P=0.007). Vision-related quality of life also improved significantly. No phototoxicity or serious safety signals were observed, supporting PBM as a promising, non-invasive, disease-modifying therapy for intermediate dry AMD.
